aTYR PHARMA (ATYR) EBT Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly EBT Margin came in at 14076.32% in Q3 2025, down 97.84% quarter-over-quarter from 7114.89% in Q1 2024.

Analysis

aTYR PHARMA (ATYR) EBT Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported EBT Margin for 6 consecutive years, with 14076.32% the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, EBT Margin changed N/A year-over-year to 14076.32%; the trailing twelve-month figure through Mar 2026 stood at 38611.05% (changed N/A YoY), and the FY2025 full-year result was 40856.32%, down 1195674.0% from the prior year.
EBT Margin slipped to 14076.32% in Q3 2025 per ATYR's latest filing, from 7114.89% in the prior quarter.
Across five years, EBT Margin topped out at 76.55% in Q4 2022 and bottomed at 14076.32% in Q3 2025.
Historically, EBT Margin has averaged 6210.35% across 4 years, with a median of 5344.27% in 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	27.53%
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	35.61%
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	-528.97%
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	35.78%
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	13.77%
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	4.84%
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	-20,427.46%
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-	-

Historic Data

Download Data